Maximizing Inhaled GLP-1 Bioavailability to Deliver Injectable-Strength Potency in a Scalable Portable Device for Improved Adherence
- Engineering next-generation dry-powder (DPI) and soft-mist (SMI) inhalation platforms to leverage the lung’s massive vascular surface area, bypassing the gastric proteolytic barrier entirely
- Utilizing proprietary formulation technologies to deliver therapeutic peptide concentrations that achieve rapid systemic absorption, rivaling the pharmacokinetics of subcutaneous injectables without the need for needles
- Optimizing high-volume, state-of-the-art manufacturing processes (139,000 sq. ft. capacity) to bypass global constraints of “cold-chain” distribution and specialized injection hardware, ensuring global scalability